Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
David Demortain. (2015) The tools of globalization: ways of regulating and the structure of the international regime for pharmaceuticals. Review of International Political Economy 22:6, pages 1249-1275.
Read now
Read now
Barbara Osimani. (2013) The precautionary principle in the pharmaceutical domain: a philosophical enquiry into probabilistic reasoning and risk aversion. Health, Risk & Society 15:2, pages 123-143.
Read now
Read now
Stuart Hogarth. (2012) Regulatory experiments and transnational networks: the governance of pharmacogenomics in Europe and the United States. Innovation: The European Journal of Social Science Research 25:4, pages 441-460.
Read now
Read now
John Abraham & Rachel Ballinger. (2012) The emergence of the genetically engineered animal models in carcinogenic risk assessment of pharmaceuticals: a case study of process innovation. New Genetics and Society 31:2, pages 223-247.
Read now
Read now
Courtney Davis & John Abraham. (2011) A comparative analysis of risk management strategies in European Union and United States pharmaceutical regulation. Health, Risk & Society 13:5, pages 413-431.
Read now
Read now
Barbara Osimani. (2010) Pharmaceutical risk communication: Sources of uncertainty and legal tools of uncertainty management. Health, Risk & Society 12:5, pages 453-469.
Read now
Read now
David Bach & AbrahamL. Newman. (2010) Governing lipitor and lipstick: Capacity, sequencing, and power in international pharmaceutical and cosmetics regulation. Review of International Political Economy 17:4, pages 665-695.
Read now
Read now
John Abraham$suffix/text()$suffix/text() & Courtney Davis. (2005) Risking public safety: Experts, the medical profession and ‘acceptable’ drug injury. Health, Risk & Society 7:4, pages 379-395.
Read now
Read now
Andy Alaszewski. (2004)
Health, Risk and Society: six years on. Health, Risk & Society 6:1, pages 3-6.
Read now
Read now
Articles from other publishers (39)
Yves-Marie Rault-Chodankar. (2022) Domestiquer la norme mondiale. Brevet pharmaceutique, bonnes pratiques de fabrication et contrôle du prix des médicaments en IndeTaming the global standard. Pharmaceutical patenting, good manufacturing practices and drug price controls in India. L’Espace Politique:45.
Crossref
Crossref
Angela De Pretto-Lazarova, Claudia Fuchs, Peter van Eeuwijk & Christian Burri. (2022) Defining clinical trial quality from the perspective of resource-limited settings: A qualitative study based on interviews with investigators, sponsors, and monitors conducting clinical trials in sub-Saharan Africa. PLOS Neglected Tropical Diseases 16:1, pages e0010121.
Crossref
Crossref
Joan Busfield. (2019) The moral economy of the pharmaceutical industry: Legitimising prices. Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine 25:3, pages 271-287.
Crossref
Crossref
Joan Busfield. (2020) Documenting the financialisation of the pharmaceutical industry. Social Science & Medicine 258, pages 113096.
Crossref
Crossref
John Abraham & Courtney Davis. (2020) International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts. Social Science & Medicine 255, pages 113005.
Crossref
Crossref
Saradindu Bhaduri & Thangminlen Kipgen. (2018) ‘New Drugs’ Approvals in India: An Institutional Perspective. Science, Technology and Society 23:3, pages 444-462.
Crossref
Crossref
Poonam Pandey & Aviram Sharma. (2019) NGOs, Controversies, and “Opening Up” of Regulatory Governance of Science in India. Bulletin of Science, Technology & Society 37:4, pages 199-211.
Crossref
Crossref
David Demortain. (2017) Expertise, Regulatory Science and the Evaluation of Technology and Risk: Introduction to the Special Issue. Minerva 55:2, pages 139-159.
Crossref
Crossref
Martino Maggetti, Christian Ewert & Philipp Trein. (2017) Not Quite the Same. The ANNALS of the American Academy of Political and Social Science 670:1, pages 152-169.
Crossref
Crossref
Ricardo Camargo & Nicolás Ried. (2015) Towards a genealogy of pharmacological practice. Medicine, Health Care and Philosophy 19:1, pages 85-94.
Crossref
Crossref
Petra Brhlikova, Ian Harper, Madhusudan Subedi, Samita Bhattarai, Nabin Rawal & Allyson M. Pollock. (2015) Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal. Globalization and Health 11:1.
Crossref
Crossref
David Demortain. 2015. La mondialisation des risques. La mondialisation des risques
109
121
.
Sergio Sismondo. 2015. International Encyclopedia of the Social & Behavioral Sciences. International Encyclopedia of the Social & Behavioral Sciences
6
10
.
Adam Hedgecoe. (2013) A deviation from standard design? Clinical trials, research ethics committees, and the regulatory co-construction of organizational deviance. Social Studies of Science 44:1, pages 59-81.
Crossref
Crossref
Joel Lexchin, Mary Wiktorowicz, Kathy Moscou & Laura Eggertson. (2013) Provincial Drug Plan Officials' Views of the Canadian Drug Safety System. Journal of Health Politics, Policy and Law 38:3, pages 545-571.
Crossref
Crossref
John Abraham & Rachel Ballinger. (2011) The Neoliberal Regulatory State, Industry Interests, and the Ideological Penetration of Scientific Knowledge. Science, Technology, & Human Values 37:5, pages 443-477.
Crossref
Crossref
John Abraham & Rachel Ballinger. (2011) Power, expertise and the limits of representative democracy: genetics as scientific progress or political legitimation in carcinogenic risk assessment of pharmaceuticals?. Journal of Community Genetics 3:2, pages 91-103.
Crossref
Crossref
Joel Lexchin. (2012) Harmony in Drug Regulation, but Who's Calling the Tune? An Examination of Regulatory Harmonization in Health Canada. International Journal of Health Services 42:1, pages 119-136.
Crossref
Crossref
Courtney Davis & John Abraham. (2011) The socio-political roots of pharmaceutical uncertainty in the evaluation of ‘innovative’ diabetes drugs in the European Union and the US. Social Science & Medicine 72:9, pages 1574-1581.
Crossref
Crossref
Edison Bicudo. (2011) “Geographical randomization” and “Social exploitation” in clinical research: World trials in Santiago, Chile. Health & Place 17:3, pages 807-813.
Crossref
Crossref
Kalman Applbaum. (2010) Shadow science: Zyprexa, Eli Lilly and the globalization of pharmaceutical damage control. BioSocieties 5:2, pages 236-255.
Crossref
Crossref
Joan Busfield. (2010) ‘A pill for every ill’: Explaining the expansion in medicine use. Social Science & Medicine 70:6, pages 934-941.
Crossref
Crossref
Joel Lexchin & Orla O'Donovan. (2010) Prohibiting or ‘managing’ conflict of interest? A review of policies and procedures in three European drug regulation agencies. Social Science & Medicine 70:5, pages 643-647.
Crossref
Crossref
JOHN ABRAHAM. (2008) Global health challenges in the pharmaceutical world. Health Economics, Policy and Law 4:01, pages 115.
Crossref
Crossref
Simon J. Williams, Jonathan Gabe & Peter Davis. (2008) The sociology of pharmaceuticals: progress and prospects. Sociology of Health & Illness 30:6, pages 813-824.
Crossref
Crossref
John Abraham. (2008) Sociology of pharmaceuticals development and regulation: a realist empirical research programme. Sociology of Health & Illness 30:6, pages 869-885.
Crossref
Crossref
Joel Lexchin. (2008) Clinical Trials in Canada: Whose Interests are Paramount?. International Journal of Health Services 38:3, pages 525-542.
Crossref
Crossref
John Abraham. (2016) Building on Sociological Understandings of the Pharmaceutical Industry or Reinventing the Wheel? Response to Joan Busfield's `Pills, Power, People'. Sociology 41:4, pages 727-736.
Crossref
Crossref
John Abraham & Courtney Davis. (2016) Deficits, Expectations and Paradigms in British and American Drug Safety Assessments. Science, Technology, & Human Values 32:4, pages 399-431.
Crossref
Crossref
J. Kent, A. Faulkner, I. Geesink & D. FitzPatrick. (2006) Towards governance of human tissue engineered technologies in Europe: Framing the case for a new regulatory regime. Technological Forecasting and Social Change 73:1, pages 41-60.
Crossref
Crossref
John Abraham & Courtney Davis. (2005) A comparative analysis of drug safety withdrawals in the UK and the US (1971–1992): Implications for current regulatory thinking and policy. Social Science & Medicine 61:5, pages 881-892.
Crossref
Crossref
David A Grimes, David Hubacher, Kavita Nanda, Kenneth F Schulz, David Moher & Douglas G Altman. (2005) The Good Clinical Practice guideline: a bronze standard for clinical research. The Lancet 366:9480, pages 172-174.
Crossref
Crossref
Karin Timmermans. (2016) Harmonization, Regulation, and Trade: Interactions in the Pharmaceutical Field. International Journal of Health Services 34:4, pages 651-661.
Crossref
Crossref
Hans Lofgren & Rebecca de Boer. (2004) Pharmaceuticals in Australia: developments in regulation and governance. Social Science & Medicine 58:12, pages 2397-2407.
Crossref
Crossref
Mary E. Wiktorowicz. (2003) Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France. Journal of Health Politics, Policy and Law 28:4, pages 615-658.
Crossref
Crossref
John Abraham & Tim Reed. (2003) Reshaping the carcinogenic risk assessment of medicines: international harmonisation for drug safety, industry/regulator efficiency or both?. Social Science & Medicine 57:2, pages 195-204.
Crossref
Crossref
John Abraham. (2003) The Science and Politics of Medicines Control. Drug Safety 26:3, pages 135-143.
Crossref
Crossref
John Abraham. (2002) The pharmaceutical industry as a political player. The Lancet 360:9344, pages 1498-1502.
Crossref
Crossref
Donald W. Light. (2013) Strengthening the Theory of Institutional Corruptions: Broadening, Clarifying, and Measuring. SSRN Electronic Journal.
Crossref
Crossref